Your browser is no longer supported. Please, upgrade your browser.
Travere Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.82 Insider Own0.90% Shs Outstand51.29M Perf Week-2.58%
Market Cap1.56B Forward P/E- EPS next Y-0.98 Insider Trans-3.05% Shs Float- Perf Month-10.41%
Income-188.80M PEG- EPS next Q-0.39 Inst Own89.10% Short Float- Perf Quarter-14.32%
Sales198.30M P/S7.88 EPS this Y-14.80% Inst Trans0.29% Short Ratio8.08 Perf Half Y17.25%
Book/sh4.12 P/B6.06 EPS next Y37.20% ROA-26.60% Target Price37.90 Perf Year85.36%
Cash/sh5.77 P/C4.32 EPS next 5Y- ROE-64.10% 52W Range13.63 - 33.09 Perf YTD-8.46%
Dividend- P/FCF- EPS past 5Y-26.80% ROI-41.30% 52W High-26.08% Beta0.68
Dividend %- Quick Ratio4.30 Sales past 5Y14.70% Gross Margin96.90% 52W Low79.46% ATR1.39
Employees262 Current Ratio4.40 Sales Q/Q9.20% Oper. Margin-88.80% RSI (14)42.11 Volatility5.20% 5.76%
OptionableYes Debt/Eq0.00 EPS Q/Q-238.50% Profit Margin-85.40% Rel Volume0.30 Prev Close24.95
ShortableYes LT Debt/Eq1.02 EarningsMar 01 AMC Payout- Avg Volume637.57K Price24.46
Recom1.30 SMA20-2.60% SMA50-10.56% SMA2004.00% Volume100,149 Change-1.96%
Apr-14-21 07:24AM  
Mar-01-21 04:01PM  
Feb-25-21 08:00AM  
Feb-22-21 04:30PM  
Feb-18-21 04:30PM  
Feb-17-21 04:05PM  
Feb-16-21 04:30PM  
Feb-11-21 10:03PM  
Feb-10-21 04:01PM  
Feb-02-21 07:00AM  
Jan-12-21 04:30PM  
Jan-11-21 07:00AM  
Dec-01-20 04:30PM  
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASELAGE STEVEDirectorMar 17Option Exercise16.2310,000162,300206,667Mar 19 04:05 PM
ASELAGE STEVEDirectorMar 17Sale27.4417,727486,456188,940Mar 19 04:05 PM